Literature DB >> 27470969

PD-1 Axis Inhibitors in EGFR- and ALK-Driven Lung Cancer: Lost Cause?

Scott Gettinger1, Katerina Politi2.   

Abstract

Programmed death axis 1 (PD-1) inhibitors have ushered in a new error of cancer immunotherapeutics for advanced smoking-associated non-small cell lung cancer. Their role in treating EGFR-mutant and ALK-rearranged lung cancer has yet to be determined. Clin Cancer Res; 22(18); 4539-41. ©2016 AACRSee related article by Gainor et al., p. 4585. ©2016 American Association for Cancer Research.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27470969      PMCID： PMC5653962          DOI： 10.1158/1078-0432.CCR-16-1401

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  10 in total

1.  Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.

Authors:  Roy S Herbst; Paul Baas; Dong-Wan Kim; Enriqueta Felip; José L Pérez-Gracia; Ji-Youn Han; Julian Molina; Joo-Hang Kim; Catherine Dubos Arvis; Myung-Ju Ahn; Margarita Majem; Mary J Fidler; Gilberto de Castro; Marcelo Garrido; Gregory M Lubiniecki; Yue Shentu; Ellie Im; Marisa Dolled-Filhart; Edward B Garon
Journal:  Lancet       Date:  2015-12-19       Impact factor: 79.321

2.  Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors.

Authors:  Esra A Akbay; Shohei Koyama; Julian Carretero; Abigail Altabef; Jeremy H Tchaicha; Camilla L Christensen; Oliver R Mikse; Andrew D Cherniack; Ellen M Beauchamp; Trevor J Pugh; Matthew D Wilkerson; Peter E Fecci; Mohit Butaney; Jacob B Reibel; Margaret Soucheray; Travis J Cohoon; Pasi A Janne; Matthew Meyerson; D Neil Hayes; Geoffrey I Shapiro; Takeshi Shimamura; Lynette M Sholl; Scott J Rodig; Gordon J Freeman; Peter S Hammerman; Glenn Dranoff; Kwok-Kin Wong
Journal:  Cancer Discov       Date:  2013-09-27       Impact factor: 39.397

3.  Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation.

Authors:  Nan Chen; Wenfeng Fang; Jianhua Zhan; Shaodong Hong; Yanna Tang; Shiyang Kang; Yaxiong Zhang; Xiaobo He; Ting Zhou; Tao Qin; Yan Huang; Xianping Yi; Li Zhang
Journal:  J Thorac Oncol       Date:  2015-06       Impact factor: 15.609

4.  Induction of PD-L1 Expression by the EML4-ALK Oncoprotein and Downstream Signaling Pathways in Non-Small Cell Lung Cancer.

Authors:  Keiichi Ota; Koichi Azuma; Akihiko Kawahara; Satoshi Hattori; Eiji Iwama; Junko Tanizaki; Taishi Harada; Koichiro Matsumoto; Koichi Takayama; Shinzo Takamori; Masayoshi Kage; Tomoaki Hoshino; Yoichi Nakanishi; Isamu Okamoto
Journal:  Clin Cancer Res       Date:  2015-05-27       Impact factor: 12.531

5.  Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1).

Authors:  Michal Marzec; Qian Zhang; Ami Goradia; Puthiyaveettil N Raghunath; Xiaobin Liu; Michele Paessler; Hong Yi Wang; Maria Wysocka; Mangeng Cheng; Bruce A Ruggeri; Mariusz A Wasik
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-16       Impact factor: 11.205

6.  Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.

Authors:  Hossein Borghaei; Luis Paz-Ares; Leora Horn; David R Spigel; Martin Steins; Neal E Ready; Laura Q Chow; Everett E Vokes; Enriqueta Felip; Esther Holgado; Fabrice Barlesi; Martin Kohlhäufl; Oscar Arrieta; Marco Angelo Burgio; Jérôme Fayette; Hervé Lena; Elena Poddubskaya; David E Gerber; Scott N Gettinger; Charles M Rudin; Naiyer Rizvi; Lucio Crinò; George R Blumenschein; Scott J Antonia; Cécile Dorange; Christopher T Harbison; Friedrich Graf Finckenstein; Julie R Brahmer
Journal:  N Engl J Med       Date:  2015-09-27       Impact factor: 91.245

7.  Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer.

Authors:  K Azuma; K Ota; A Kawahara; S Hattori; E Iwama; T Harada; K Matsumoto; K Takayama; S Takamori; M Kage; T Hoshino; Y Nakanishi; I Okamoto
Journal:  Ann Oncol       Date:  2014-07-09       Impact factor: 32.976

8.  Upregulation of PD-L1 by EML4-ALK fusion protein mediates the immune escape in ALK positive NSCLC: Implication for optional anti-PD-1/PD-L1 immune therapy for ALK-TKIs sensitive and resistant NSCLC patients.

Authors:  Shaodong Hong; Nan Chen; Wenfeng Fang; Jianhua Zhan; Qing Liu; Shiyang Kang; Xiaobo He; Lin Liu; Ting Zhou; Jiaxing Huang; Ying Chen; Tao Qin; Yaxiong Zhang; Yuxiang Ma; Yunpeng Yang; Yuanyuan Zhao; Yan Huang; Li Zhang
Journal:  Oncoimmunology       Date:  2015-12-21       Impact factor: 8.110

9.  EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis.

Authors:  Justin F Gainor; Alice T Shaw; Lecia V Sequist; Xiujun Fu; Christopher G Azzoli; Zofia Piotrowska; Tiffany G Huynh; Ling Zhao; Linnea Fulton; Katherine R Schultz; Emily Howe; Anna F Farago; Ryan J Sullivan; James R Stone; Subba Digumarthy; Teresa Moran; Aaron N Hata; Yukako Yagi; Beow Y Yeap; Jeffrey A Engelman; Mari Mino-Kenudson
Journal:  Clin Cancer Res       Date:  2016-05-25       Impact factor: 12.531

10.  PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients.

Authors:  A D'Incecco; M Andreozzi; V Ludovini; E Rossi; A Capodanno; L Landi; C Tibaldi; G Minuti; J Salvini; E Coppi; A Chella; G Fontanini; M E Filice; L Tornillo; R M Incensati; S Sani; L Crinò; L Terracciano; F Cappuzzo
Journal:  Br J Cancer       Date:  2014-10-28       Impact factor: 7.640
  10 in total
  12 in total

Review 1.  Third-generation epidermal growth factor receptor-tyrosine kinase inhibitors in T790M-positive non-small cell lung cancer: review on emerged mechanisms of resistance.

Authors:  Roberta Minari; Paola Bordi; Marcello Tiseo
Journal:  Transl Lung Cancer Res       Date:  2016-12

Review 2.  Immunotherapy in the Asiatic population: any differences from Caucasian population?

Authors:  Lunxi Peng; Yi-Long Wu
Journal:  J Thorac Dis       Date:  2018-05       Impact factor: 2.895

3.  Cons: should immunotherapy be incorporated in the treatment of oncogene-driven lung cancer?

Authors:  Giulio Metro; Massimo Di Maio
Journal:  Transl Lung Cancer Res       Date:  2018-09

4.  EGFR mutation correlates with uninflamed phenotype and weak immunogenicity, causing impaired response to PD-1 blockade in non-small cell lung cancer.

Authors:  Zhong-Yi Dong; Jia-Tao Zhang; Si-Yang Liu; Jian Su; Chao Zhang; Zhi Xie; Qing Zhou; Hai-Yan Tu; Chong-Rui Xu; Li-Xu Yan; Yu-Fa Li; Wen-Zhao Zhong; Yi-Long Wu
Journal:  Oncoimmunology       Date:  2017-07-26       Impact factor: 8.110

Review 5.  Sequencing of ALK Inhibitors in ALK+ Non-Small Cell Lung Cancer.

Authors:  Shirish M Gadgeel
Journal:  Curr Treat Options Oncol       Date:  2017-06

6.  Efficacy of Atezolizumab for Advanced Non-Small Cell Lung Cancer Based on Clinical and Molecular Features: A Meta-Analysis.

Authors:  Wenjie Liu; Gengwei Huo; Peng Chen
Journal:  Front Immunol       Date:  2022-06-21       Impact factor: 8.786

Review 7.  Targeting EGFR in Lung Cancer: Current Standards and Developments.

Authors:  Asunción Díaz-Serrano; Pablo Gella; Elisabeth Jiménez; Jon Zugazagoitia; Luis Paz-Ares Rodríguez
Journal:  Drugs       Date:  2018-06       Impact factor: 9.546

8.  Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry.

Authors:  J Mazieres; A Drilon; A Lusque; L Mhanna; A B Cortot; L Mezquita; A A Thai; C Mascaux; S Couraud; R Veillon; M Van den Heuvel; J Neal; N Peled; M Früh; T L Ng; V Gounant; S Popat; J Diebold; J Sabari; V W Zhu; S I Rothschild; P Bironzo; A Martinez-Marti; A Curioni-Fontecedro; R Rosell; M Lattuca-Truc; M Wiesweg; B Besse; B Solomon; F Barlesi; R D Schouten; H Wakelee; D R Camidge; G Zalcman; S Novello; S I Ou; J Milia; O Gautschi
Journal:  Ann Oncol       Date:  2019-08-01       Impact factor: 32.976

Review 9.  When to Consider Immune Checkpoint Inhibitors in Oncogene-Driven Non-Small Cell Lung Cancer?

Authors:  Laurent Mhanna; Nicolas Guibert; Julie Milia; Julien Mazieres
Journal:  Curr Treat Options Oncol       Date:  2019-06-06

10.  Tumor regression mediated by oncogene withdrawal or erlotinib stimulates infiltration of inflammatory immune cells in EGFR mutant lung tumors.

Authors:  Deborah Ayeni; Braden Miller; Alexandra Kuhlmann; Ping-Chih Ho; Camila Robles-Oteiza; Mmaserame Gaefele; Stellar Levy; Fernando J de Miguel; Curtis Perry; Tianxia Guan; Gerald Krystal; William Lockwood; Daniel Zelterman; Robert Homer; Zongzhi Liu; Susan Kaech; Katerina Politi
Journal:  J Immunother Cancer       Date:  2019-07-10       Impact factor: 12.469
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.